An 8 Week, Double-Blind, Randomized, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren /Amlodipine / HCTZ in Patients With Moderate to Severe Hypertension.

Trial Profile

An 8 Week, Double-Blind, Randomized, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren /Amlodipine / HCTZ in Patients With Moderate to Severe Hypertension.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 May 2016

At a glance

  • Drugs Aliskiren/amlodipine/hydrochlorothiazide (Primary) ; Aliskiren/amlodipine; Aliskiren/hydrochlorothiazide; Amlodipine/hydrochlorothiazide
  • Indications Essential hypertension
  • Focus Biomarker; Registrational; Therapeutic Use
  • Most Recent Events

    • 22 Jul 2012 Results published in the Journal of Hypertension.
    • 23 Dec 2010 Based on results from this study, the US FDA has approved Amturnide, a fixed combination of aliskiren/amlodipine/hydrochlorothiazide, for the treatment of hypertension, according to a Novartis media release.
    • 30 Sep 2010 Results from a subset of patients presented at the 23rd Scientific Meeting of the International Society of Hypertension.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top